Table 3.
Treatment Emergent Adverse Events
| Site | No. of Events for Bevacizumab-Only Arm | No. of Events for Bevacizumab + Fosbretabulin–Arm | ||||||
|---|---|---|---|---|---|---|---|---|
| Grade 2 | Grade 3 | Grade 4 | Grade 5 | Grade 2 | Grade 3 | Grade 4 | Grade 5 | |
| Blood/lymphatics | 7 | 0 | 0 | 0 | 3 | 1 | 0 | 0 |
| GI | 10 | 6 | 0 | 0 | 12 | 10 | 0 | 1* |
| General/administration site | 13 | 2 | 0 | 0 | 17 | 3 | 0 | 0 |
| Infections/infestations | 19 | 3 | 0 | 0 | 18 | 3 | 0 | 0 |
| Investigation site | 11 | 4 | 0 | 0 | 6 | 5 | 0 | 0 |
| Metabolism/nutrition | 11 | 7 | 1 | 0 | 7 | 11 | 0 | 0 |
| Musculoskeletal/connective tissue | 14 | 2 | 0 | 0 | 6 | 2 | 0 | 0 |
| Nervous system | 6 | 1 | 0 | 0 | 7 | 3 | 0 | 0 |
| Renal/urinary | 5 | 0 | 0 | 0 | 4 | 2 | 0 | 0 |
| Respiratory/thoracic/mediastinal | 10 | 2 | 0 | 0 | 5 | 1 | 0 | 0 |
| Vascular disorders | 13 | 10 | 0 | 0 | 13 | 18† | 1 | 0 |
*
Grade 5 GI was gastric obstruction, considered not related to treatment.
†
Includes 17 for hypertension and one for a thromboembolic event.